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ABSTRACT
Background A recent randomised controlled
trial (RCT) of acupuncture as a treatment for
irritable bowel syndrome (IBS) demonstrated
sustained benefits over a period of 12 months
post-randomisation.
Aim To extend the trial follow-up to evaluate
the effects of acupuncture at 24 months post-
randomisation.
Methods Patients in primary care with ongoing
IBS were recruited to a two-arm pragmatic RCT
of acupuncture for IBS. Participants were
randomised to the offer of up to 10 weekly
sessions of acupuncture plus usual care (n=116
patients) or to continue with usual care alone
(n=117). The primary outcome was the self-
reported IBS symptom severity score (IBS SSS)
measured at 24 months post-randomisation.
Analysis was by intention-to-treat using an
unstructured multivariate linear model
incorporating all repeated measures.
Results The overall response rate was 61%. The
adjusted difference in mean IBS SSS at
24 months was −18.28 (95% CI −40.95 to 4.40)
in favour of the acupuncture arm. Differences at
earlier time points estimated from the
multivariate model were: −27.27 (−47.69 to
−6.86) at 3 months; −23.69 (−45.17 to −2.21)
at 6 months; −24.09 (−45.59 to −2.59) at
9 months; and −23.06 (−44.52 to −1.59) at
12 months.
Conclusions There were no statistically
significant differences between the acupuncture
and usual care groups in IBS SSS at 24 months
post-randomisation, and the point estimate for
the mean difference was approximately 80% of
the size of the statistically significant results seen
at 6, 9 and 12 months.
Trial registration number ISRCTN08827905.
INTRODUCTION
In response to the limited evidence on
acupuncture as a treatment for patients
with irritable bowel syndrome (IBS), as
detailed in a Cochrane review,1 we previ-
ously conducted a pragmatic randomised
controlled trial (RCT) to evaluate the clin-
ical effectiveness and cost-effectiveness of
acupuncture for this condition.2 3 We
found that, for patients recruited from
primary care who were diagnosed with
IBS with an average duration of 13 years,
acupuncture was associated with a clinical
reduction in symptoms at 3 months post-
randomisation when compared to usual
care alone, and that the effect largely
persisted up to 12 months post-
randomisation.2
We know from a previous trial of acu-
puncture for low back pain that statistic-
ally significant benefits might be observed
at 24 months post-randomisation.4 Such
long-term benefits are hypothesised to be
associated with the acupuncture-specific
interactions designed to engage patients
in their recovery process by making, for
example, lifestyle changes indicated by
their traditional acupuncture diagnosis.5
Similarly, in the aforementioned trial of
acupuncture for IBS, the acupuncturists
provided lifestyle advice to 68% of their
patients.6
In the light of uncertainty regarding
whether clinical benefits in IBS lasted
beyond 12 months, our aim was to
extend the project and conduct a longer-
term follow-up at 24 months post-
randomisation.
METHODS
Design
The methods for the full-scale trial are
reported elsewhere.2 In summary, 233
adults with IBS symptoms scoring at least
100 on the IBS symptom severity scale
(IBS SSS) were recruited from primary
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care to a parallel-arm RCT examining the clinical
effectiveness and cost-effectiveness of acupuncture as
an adjunct to usual care for IBS. The patients were
recruited from November 2008 to June 2009. The
trial was prospectively registered (ISRCTN08827905)
and received approval from the York NHS Research
Ethics Committee (08/H1311/66) in 2008.
Randomisation and interventions
Patients were randomly allocated to receive up to 10
weekly individualised sessions of acupuncture plus
usual care (n=116) or to continue with usual care
alone (n=117). The random allocation sequence was
computer-generated by an independent data manager
in the York Trials Unit. Those allocated to the acu-
puncture group were offered up to 10 sessions.
Patients who attended at least one session completed
on average nine sessions, almost all of which were
delivered weekly in the first 3 months post-
randomisation. Details of the traditional acupuncture
diagnosis and treatment, including the acupuncture
diagnosis-related lifestyle advice, have been published
separately.6
Outcome measures
Initially we sent follow-up questionnaires by post to
patients at 3, 6, 9, and 12 months post-randomisation.
The main outcome measure was the IBS SSS, which is
scored from 0 to 500 (<75=no IBS, 75–175=‘mild’
IBS, 175–300=‘moderate’ IBS, >300=‘severe’ IBS).7
Secondary outcomes included the IBS non-colonic
symptom score (NCSS), which includes lethargy and
tiredness, backache, and other symptoms,8 and the
12-item Short Form Health Survey (SF-12) physical
component summary (PCS) and mental component
summary (MCS) scores.9 In this extended follow-up
study, the above outcomes were measured at a single
additional time point (24 months post-
randomisation).
Ethics approval and follow-up method
Approval for this project extension was obtained from
the York NHS Research Ethics Committee (08/
H1311/66). A letter was sent to all patients who had
not withdrawn from the trial informing them of the
new follow-up in June 2011. If letters were returned
undelivered because the addressee had moved, we
tried to make contact with the patient by phone to
obtain his or her new postal address. A few weeks
after the initial letter had been mailed out, the new
follow-up questionnaire was posted to all patients
who had not withdrawn from the trial and for whom
we had addresses. Questionnaires were sent out on
the same date to all participants. At the point we were
able to commence follow-up, it had been 30 and
24 months since the first and last patients, respect-
ively, had been recruited to the trial. If patients did
not return the questionnaire, we did not send a
reminder letter or seek to collect the outcomes over
the phone. Return of the additional follow-up ques-
tionnaire from patients was taken to indicate implicit
consent to take part.
Statistical analysis
We used Stata (V.12) to perform intention-to-treat stat-
istical analysis of the IBS SSS measures using a two-
sided 5% significance level. In our earlier paper2 we
used standard analysis of covariance (ANCOVA)
models to compare means in the two groups, adjust-
ing for baseline levels separately at each follow-up
time point. Here, in view of the fact that there was
substantially more missing data at 24 months, we used
a multivariate linear model to analyse simultaneously
the data from all time points. The advantage of this
approach is that it can take account of some of the
biases that can be introduced by missing data. A prop-
erly specified multivariate model is unbiased under a
‘missing at random’ assumption whereas ANCOVA
requires the stronger ‘missing completely at random’
assumption.10
This multivariate model has been described in detail
by Molenberghs and Kenward11 and Carpenter and
Kenward.12 In brief, the model treats the baseline and
follow-up measures as correlated outcomes, enforcing
a zero treatment effect at baseline, with an unstruc-
tured covariance matrix for the repeated measures.
The model permits simultaneous estimation of treat-
ment differences at all follow-up time-points, adjusted
for baseline. It is evident from the findings of Lee13
that, in the absence of missing data, this approach
gives identical point estimates and very similar stand-
ard errors to an ANCOVA model. It also allows mea-
surements at the various time points (including
baseline) to be correlated one with another, with no
constraints on variance and covariance. White and
Thompson have shown analytically and in simulations
that this approach is the most statistically efficient
method of dealing with partially missing baseline mea-
surements in RCTs.14 Analogous analyses were per-
formed for the secondary outcomes of IBS NCSS and
SF-12 PCS and MCS scores.
RESULTS
Recruitment and follow-up
The baseline characteristics of the 233 patients
recruited to the trial are published elsewhere.2 In
brief, the average age was 43 years, 19% were male,
and they had experienced IBS for an average of
13 years. Follow-up rates are presented in table 1,
which shows that complete non-missing IBS SSS data
at 24 months were available for analysis in 61% of
participants, comprising 68% (n=79) of the acupunc-
ture group and 53% (n=62) of the usual care group.
Table 2 shows the mean baseline IBS SSS for those
with and without available data at 24 months.
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Results from the unstructured multivariate linear
model analysis of IBS SSS, treating follow-up and
baseline IBS SSS measures as correlated outcomes
with only that of follow-up depending on treatment,
are shown in table 3 and figure 1. Up to 12 months,
this analysis gave results that were largely similar to
the separate linear regression models used previously.2
The adjusted difference between the means at
24 months (−18.28, 95% CI −40.95 to 4.40) was not
statistically significant, and the point estimate was
around 20% smaller in magnitude than the mean dif-
ferences of 23 to 24 points that were seen at 6, 9, and
12 months. A minor difference compared to our pre-
vious analysis was the finding of a statistically signifi-
cant difference between acupuncture and usual care
groups at 12 months (−23.06, 95% CI −44.52 to
−1.59; p=0.035), which was previously only border-
line significant (−21.33, 95% CI −43.66 to 1.00;
p=0.061). The re-analysis of all available data under a
missing at random assumption resulted in a slightly
larger treatment effect that was more precisely esti-
mated, as demonstrated by the tighter confidence
interval.
Between-group differences for the IBS NCSS, SF-12
PCS and SF-12 MCS scores, derived using the
unstructured multivariate linear model, are presented
in table 4. Baseline and follow-up scores were treated
as correlated outcomes, with only that of follow-up
depending on treatment. There were no significant
differences in outcome between the two groups with
the single exception of the NCSS at 3 months.
Table 2 Baseline IBS SSS according to whether or not an
IBS SSS score was obtained at 24 months
24 month score
obtained—mean (SE)
24 month score missing
—mean (SE)
Acupuncture
group
269.13 (8.79) n=78 302.92 (14.02) n=37
Usual care
group
273.67 (8.73) n=61 281.27 (10.49) n=52
Of those providing follow-up data at 24 months, baseline IBS SSS data
were available for 78 of 79 patients in the acupuncture group and 61 of
62 patients in the usual care group.
IBS SSS, irritable bowel syndrome symptom severity score.
Table 1 Response rates at follow-up for acupuncture (n=116)
and usual care (n=117)
Month
Questionnaires returned
(%)
Non-missing IBS SSS data
(%)
Acupuncture Usual care Acupuncture Usual care
3 109 (94%) 100 (85%) 108 (93%) 97 (83%)
6 105 (91%) 95 (81%) 99 (85%) 91 (78%)
9 104 (90%) 95 (81%) 93 (80%) 94 (80%)
12 104 (90%) 94 (80%) 103 (89%) 93 (79%)
24 81 (70%) 62 (53%) 79 (68%) 62 (53%)
IBS SSS, irritable bowel syndrome symptom severity score.
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DISCUSSION
Principal findings
In extending the collection of outcome data to
24 months, there were considerable missing data,
with only 61% of participants providing complete
IBS SSS data. Using an unstructured multivariate
linear model to analyse data simultaneously from all
time points, an approach which is more robust with
regard to missing data than the separate complete
case analysis method used previously, we did not
observe a statistically significant difference in IBS
symptom scores between the two groups at
24 months. Moreover, the point estimate of the size
of the (non-significant) between-group difference
was reduced by approximately 20% compared with
that seen at 12 months, which was borderline statis-
tically significant (p=0.061) in our original report2
and formally significant (p=0.035) after switching
to an unstructured multivariate linear model herein
—although it should be noted that the absolute
change in p value and 95% confidence limits were
small. The lack of a statistically significant treatment
effect at 24 months could be due in part to the
small size of the remaining sample and the concur-
rent, progressive reduction in IBS symptoms in the
usual care group between 12 and 24 months. It is
also noteworthy that the 68% of participants in the
acupuncture group that provided data at 24 months
had lower IBS SSS scores at baseline than the 32%
who did not, and may not therefore be fully repre-
sentative of the treatment group as a whole. Despite
the fact that our approach to the statistical analysis
controls for some of the biases that can result
through missing data, it is still possible that this
baseline difference between those with and without
follow-up data at 24 months could have biased our
results. As per our previously published analysis,2
we found little in the way of meaningful differences
for any secondary outcomes measures—that is, non-
colonic IBS symptoms and SF-12 physical and
mental component scores.
Strengths and limitations
The major strength of this study is its long-term
follow-up through to 24 months post-randomisation,
a length of time that is unusual in studies of treat-
ments for IBS. Moreover, our use of unstructured
multivariate linear models (with baseline IBS SSS as a
correlated outcome measure as opposed to a covari-
ate) controls better for the potential biases that can
arise due to missing data. This approach also led to a
slightly more precise estimation of the treatment
effects, as reflected in the somewhat tighter confi-
dence intervals. We found that more patients in the
usual care group failed to provide data at 24 months
compared to the acupuncture group (47% vs 32%)
and that the 68% of patients in the acupuncture
group who did provide data at 24 months had a
higher baseline IBS SSS than the 32% who did not.
As such, those participants with extended follow-up
may not be fully representative of the original groups
as a whole, which could potentially introduce bias.
These differences provide a rationale for the unstruc-
tured multivariate linear model as it relaxes the
assumptions necessary for the treatment estimates to
be unbiased.
The low response rate at 24 months is a major limi-
tation, especially given that response rates at 3, 6, 9,
and 12 months were relatively high, with question-
naires returned by ≥90% and ≥80% of the acupunc-
ture and usual care groups, respectively.2 At
24 months, we only received follow-up questionnaires
with complete data from 61% of participants across
the two trial arms. This could be due in part to the
fact that the long-term follow-up at 24 months was
not part of the original trial design. Patients participat-
ing in the trial originally expected a 12-month com-
mitment and may thus have been less willing to return
a subsequent and additional questionnaire, given that
they were not informed of this possibility at the time
of initial consent. In some cases, we no longer had the
current address for patients, as some had moved away
since the point of last contact by the trial team for
completion of the 12-month questionnaire.
As mentioned above, the loss to follow-up was not
evenly split between groups, with only 53% of the
usual care group submitting IBS SSS data at
24 months, compared to 68% in the acupuncture
arm. The reason for this difference is unknown;
however, the greater participation with regards to
follow-up in the acupuncture group may reflect the
enhanced engagement with the trial engendered by
practitioner–patient interactions that only occurred in
the acupuncture arm during the first 3 months of the
trial. The difference in response rates illustrates the
need for the multivariate model. The difference sug-
gests that the ‘missing completely at random’ assump-
tion necessary for simpler analyses to be unbiased is
implausible here. Another limitation is that, after the
end of the initial 12-month trial period, additional
Figure 1 Unstructured multivariate linear model predicted
means and 95% CIs. IBS, irritable bowel syndrome.
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Table 4 Secondary outcome measures between baseline and 24-month follow-up, and between-group differences (n=233)
Month 0 mean
(95% CI)
Month 3 mean
(95% CI)
Month 6 mean
(95% CI)
Month 9 mean
(95% CI)
Month 12 mean
(95% CI)
Month 24 mean
(95% CI)
IBS NCSS
Acupuncture group (n=116) 208.71 (198.94 to
218.47)
178.78 (166.22 to 191.34) 181.43 (168.41 to 194.46) 187.12 (172.64 to 201.60) 186.93 (173.07 to 200.79) 178.11 (164.08 to 192.14)
Usual care group (n=117) 193.42 (180.57 to 206.28) 188.79 (175.45 to 202.13) 189.81 (175.13 to 204.49) 194.73 (180.44 to 209.03) 188.16 (173.00 to 203.32)
Between-group differences in means
(acupuncture vs. usual care)
− −14.64 (−28.91 to −0.38)* −7.36 (−23.08 to 8.36) −2.69 (−20.14 to 14.76) −7.80 (−24.51 to 8.90) −10.05 (−27.67 to 7.56)
SF-12 PCS score
Acupuncture group (n=116) 43.38 (42.56 to
44.21)
42.82 (41.78 to 43.86) 43.11 (42.06 to 44.16) 42.34 (41.29 to 43.39) 42.09 (41.10 to 43.07) 42.30 (41.21 to 43.39)
Usual care group (n=117) 42.72 (41.59 to 43.84) 42.14 (41.03 to 43.26) 43.12 (42.01 to 44.22) 42.15 (41.11 to 43.20) 41.62 (40.43 to 42.81)
Between-group differences in means
(acupuncture vs. usual care)
− 0.10 (−1.26 to 1.47) 0.97 (−0.35 to 2.29) −0.78 (−2.14 to 0.58) −0.07 (−1.37 to 1.24) 0.68 (−0.73 to 2.09)
SF-12 MCS score
Acupuncture group (n=116) 44.08 (42.64 to
45.52)
46.32 (44.39 to 48.25) 46.02 (44.06 to 47.99) 46.70 (44.72 to 48.69) 46.39 (44.43 to 48.35) 47.35 (45.39 to 49.30)
Usual care group (n=117) 44.95 (42.84 to 47.05) 44.91 (42.81 to 47.00) 45.15 (43.07 to 47.22) 45.98 (43.91 to 48.04) 46.86 (44.71 to 49.00)
Between-group differences in means
(acupuncture vs. usual care)
− 1.37 (−1.24 to 3.99) 1.12 (−1.52 to 3.75) 1.56 (−1.02 to 4.14) 0.41 (−2.14 to 2.96) 0.49 (−2.18 to 3.15)
Data are predicted means and 95% CIs from the fitted model. At month 0 there is only one predicted mean for each measure since the corresponding outcome does not depend on treatment.
*p<0.05.
IBS NCSS, irritable bowel syndrome non-colonic symptom score; MCS, mental component summary; PCS, physical component summary; SF-12, 12-item Short Form Health Survey.
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acupuncture treatments may have been received by
some patients in either arm, and this could have influ-
enced the results either way.
The results of the trial can only be generalised with
caution. The patients recruited to the trial constituted
people who had consulted their general practitioner in
primary care, had been diagnosed as having IBS of an
average duration of 13 years, and were continuing to
experience IBS symptoms. The results we have pre-
sented are based on averages across this population. A
consequence of the small sample size is that we were
unable to conduct subgroup analyses—for example,
comparing patients with more severe or less severe IBS.
Implications for research and practice
As previously acknowledged, the trial was not
designed to establish the proportion of the overall
benefit that might be associated with ‘non-specific
effects’—for example, the generic benefits associated
with consulting an empathetic acupuncture practi-
tioner in a supportive environment. Our extension of
the follow-up to 24 months provides further evidence
that the benefits observed between 3 and 12 months
post-randomisation are unlikely to be due to ‘non-
specific effects’. External evidence to support this
comes from a review of 27 RCTs of treatments for
IBS, in which no individual trial demonstrated a
placebo response at 12 months.15 That the IBS
symptom scores are largely sustained between the end
of treatment at 3 months through to 24 months sug-
gests that the apparent benefits of acupuncture repre-
sent more than a simple placebo response.
Longer-term effects are likely to be associated with
the underlying physiological mechanisms of action,
into which further research is required. Also poten-
tially important over the longer term are the non-
needling components of treatment that are
acupuncture-specific, such as the explanations of the
traditional acupuncture diagnosis and the active
engagement of the patient in following lifestyle advice
related to the diagnosis.2 6
In terms of future trial design, it would be useful to
control for the extra time and attention that the
patients in the acupuncture arm received. For
example, this could be provided by an active control
arm with an intervention perceived to be credible by
patients that provides structural equivalence in terms
of measurable non-specific treatment components.
Possible active controls in trials of acupuncture for
IBS might include hypnotherapy, cognitive behav-
ioural therapy, relaxation, and/or nutritional guidance.
Among a range of possible non-specific components
that one might want to control for, clearly contact
time is important, as well as the quality of attention
provided by the practitioner. As an exemplar, in a pre-
vious study of acupuncture for depression,16 counsel-
ling was provided as an active control, contact time
and empathy were assessed using the consultation and
relational empathy (CARE) measure,17 and these vari-
ables were included in the analysis comparing acu-
puncture with counselling.
CONCLUSION
There were no significant differences between the acu-
puncture and usual care groups at 24 months post-
randomisation, and the point estimate for the mean
difference was reduced by approximately 20% com-
pared to the previous time point of 12 months. Using
analytical methods that are more robust to the effects
of missing data, we found statistically significant dif-
ferences favouring acupuncture at 12 months, which
only represented a statistical tendency in our previous
analysis. The lack of a statistically significant differ-
ence at 24 months may be associated, at least in part,
with the progressive improvement observed within
the usual care group, combined with the increased
loss to follow-up over time.
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